Chang-Long Chen

791 total citations
17 papers, 611 citations indexed

About

Chang-Long Chen is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Chang-Long Chen has authored 17 papers receiving a total of 611 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 8 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in Chang-Long Chen's work include Cancer Immunotherapy and Biomarkers (7 papers), Immune Cell Function and Interaction (5 papers) and Immunotherapy and Immune Responses (4 papers). Chang-Long Chen is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Immune Cell Function and Interaction (5 papers) and Immunotherapy and Immune Responses (4 papers). Chang-Long Chen collaborates with scholars based in China. Chang-Long Chen's co-authors include Jian‐Chuan Xia, De-Sheng Weng, Jing-Jing Zhao, Xiaofei Zhang, Qiu-Zhong Pan, Zi-Qi Zhou, Shan-Shan Jiang, Hong-Xia Zhang, Qi-Jing Wang and Qian Zhu and has published in prestigious journals such as Stem Cells, Oncotarget and BMC Cancer.

In The Last Decade

Chang-Long Chen

17 papers receiving 610 citations

Peers

Chang-Long Chen

ONCOL

IMMUN

PRM

Hengkang Liu China

Jinghui Cheng China

Prashanth Prithviraj Australia

Antonio Cusmai Italy

Jianbo Zhang China

Yuka Inoue Japan

Bernadette Reyna Asuncion United States

Gataree Ngarmchamnanrith United States

Wei‐Feng Qu China

Jaykumar Thumar United States

Hengkang Liu China

Chang-Long Chen

263 ×0.7

ONCOL

280 ×1.3

IMMUN

264 ×1.3

170 ×1.3

105 ×1.0

PRM

Citations per year, relative to Chang-Long Chen Chang-Long Chen (= 1×) peers Hengkang Liu

Countries citing papers authored by Chang-Long Chen

Since Specialization

Citations

This map shows the geographic impact of Chang-Long Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chang-Long Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chang-Long Chen more than expected).

Fields of papers citing papers by Chang-Long Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chang-Long Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chang-Long Chen. The network helps show where Chang-Long Chen may publish in the future.

Co-authorship network of co-authors of Chang-Long Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Chang-Long Chen. A scholar is included among the top collaborators of Chang-Long Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chang-Long Chen. Chang-Long Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Zhou, Zi-Qi, Jing-Jing Zhao, Qiu-Zhong Pan, et al.. (2019). PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer. Journal for ImmunoTherapy of Cancer. 7(1). 228–228. 27 indexed citations

Zhao, Jing-Jing, Chang-Long Chen, Hong-Xia Zhang, et al.. (2018). Clinical Effect of Adjuvant Cytokine-Induced Killer Cells Immunotherapy in Patients with Stage II-IVB Nasopharyngeal Carcinoma after Chemoradiotherapy: A propensity score analysis. Journal of Cancer. 9(22). 4204–4214. 4 indexed citations

Zhou, Yun, Chang-Long Chen, Yanling Feng, et al.. (2018). Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy. OncoImmunology. 8(2). e1528411–e1528411. 24 indexed citations

Zhou, Zi-Qi, Xiaofei Zhang, Chang-Long Chen, et al.. (2017). Overexpression of SMOC2 Attenuates the Tumorigenicity of Hepatocellular Carcinoma Cells and Is Associated With a Positive Postoperative Prognosis in Human Hepatocellular Carcinoma. Journal of Cancer. 8(18). 3812–3827. 13 indexed citations

Zhu, Qian, Hao Hu, De-Sheng Weng, et al.. (2017). Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC. BMC Cancer. 17(1). 412–412. 22 indexed citations

Chen, Chang-Long, Qiu-Zhong Pan, De-Sheng Weng, et al.. (2017). Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors. OncoImmunology. 7(4). e1417721–e1417721. 42 indexed citations

Zhu, Qian, Mu-Yan Cai, Chang-Long Chen, et al.. (2017). Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes. OncoImmunology. 6(5). e1312240–e1312240. 67 indexed citations

Chen, Chang-Long, Ying Wang, Chun-yu Huang, et al.. (2017). IL-17 induces antitumor immunity by promoting beneficial neutrophil recruitment and activation in esophageal squamous cell carcinoma. OncoImmunology. 7(1). e1373234–e1373234. 57 indexed citations

Chen, Chang-Long, Qiu-Zhong Pan, Jing-Jing Zhao, et al.. (2016). PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. OncoImmunology. 5(7). e1176653–e1176653. 51 indexed citations

10.

Jiang, Shan-Shan, De-Sheng Weng, Long Jiang, et al.. (2016). The clinical significance of preoperative serum cholesterol and high-density lipoprotein-cholesterol levels in hepatocellular carcinoma. Journal of Cancer. 7(6). 626–632. 59 indexed citations

11.

Zhang, Xiaofei, Ke Pan, De-Sheng Weng, et al.. (2016). Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosis. Oncotarget. 7(18). 26670–26679. 56 indexed citations

12.

Chen, Chang-Long, Ying Wang, Qiu-Zhong Pan, et al.. (2016). Bromodomain-containing protein 7 (BRD7) as a potential tumor suppressor in hepatocellular carcinoma. Oncotarget. 7(13). 16248–16261. 22 indexed citations

13.

Zhang, Xiaofei, Jie Chao, Qiu-Zhong Pan, et al.. (2015). Overexpression of WWP1 Promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma. Oncotarget. 6(38). 40920–40933. 28 indexed citations

14.

Zhang, Hong-Xia, Shan-Shan Jiang, Xiaofei Zhang, et al.. (2015). Protein kinase CK2α catalytic subunit is overexpressed and serves as an unfavorable prognostic marker in primary hepatocellular carcinoma. Oncotarget. 6(33). 34800–34817. 48 indexed citations

15.

Jiang, Shan-Shan, Xiao Hai Li, Yin Li, et al.. (2015). A novel pathogenic germline mutation in the adenomatous polyposis coli gene in a Chinese family with familial adenomatous coli. Oncotarget. 6(29). 27267–27274. 9 indexed citations

16.

Wang, Ying, Chang-Long Chen, Qiu-Zhong Pan, et al.. (2015). Decreased TPD52 expression is associated with poor prognosis in primary hepatocellular carcinoma. Oncotarget. 7(5). 6323–6334. 26 indexed citations

17.

Pan, Qiu-Zhong, Ke Pan, Qi-Jing Wang, et al.. (2014). Annexin A3 as a Potential Target for Immunotherapy of Liver Cancer Stem-Like Cells. Stem Cells. 33(2). 354–366. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact